2024-02-022024-02-022014-02-14Yazıcı, B. vd. (2013). "Orbital cavitary rhabdomyosarcoma: Case report and literature review". Ophthalmic Plastic and Reconstructive Surgery, 30(1), E20-E22.0740-9303https://journals.lww.com/oprs/fulltext/2014/01000/orbital_cavitary_rhabdomyosarcoma__case_report_and.43.aspxhttps://hdl.handle.net/11452/39450Orbital cavitary rhabdomyosarcoma has been previously reported in 2 cases. The case presented here was a 15-year-old boy who had proptosis, pain, periorbital hyperemia, and visual loss in his OD, which progressed in 6 weeks. Radiologic studies demonstrated a well-demarcated, multilobulated, large mass with cavities, extending from the anterior orbit to the apex, suggesting a diagnosis of venolymphatic malformation with an intrinsic hemorrhage. On surgery, a multilobular, hemorrhagic cystic mass was almost completely excised. Histologic examination revealed a diagnosis of embryonal rhabdomyosarcoma. After postoperative chemotherapy and radiotherapy, the tumor did not recur during a follow-up period of 45 months. This case, together with the previous ones, suggests that cavitary orbital rhabdomyosarcomas may have some distinct clinical, radiologic, and surgical characteristics.eninfo:eu-repo/semantics/closedAccessOphthalmologySurgeryAdolescentHumansMagnetic resonance imagingMaleOculomotor musclesOrbital neoplasmsRhabdomyosarcoma, alveolarTomography, x-ray computedVisual acuityOrbital cavitary rhabdomyosarcoma: Case report and literature reviewArticle0003355596000152-s2.0-84893653480E20E2230123552609https://doi.org/10.1097/IOP.0b013e31828de376OphthalmologySurgeryRhabdomyosarcoma; Sarcoma; BrachytherapyAdolescentAfferent pupillary defectArticleBleedingCancer chemotherapyCancer radiotherapyCancer surgeryCase reportComputer assisted tomographyDisease severityEmbryonal rhabdomyosarcomaExophthalmosFollow upHistologyHumanImmunohistochemistryLymphatic malformationMaleNuclear magnetic resonance imagingOrbital cavitary rhabdomyosarcomaPostoperative periodPriority journalRadiation doseVisual acuityVisual impairmentAntineoplastic agentDesminMyogeninVimentin1537-2677